Article PDF first page preview

First page of Impact of implementing nasal high flow therapy on body growth in preterm infants

Introduction: The objective of this study was to determine the impact of nasal high flow (nHF) implementation on lung growth at six months corrected age (CA) in preterm infants. Methods: This single-center retrospective cohort study included preterm infants born <30 weeks gestation' and surviving to six months CA at the neonatal intensive care unit of the Amsterdam University Medical Centers. In the nCPAP cohort (2009-2012), continuous distending pressure (CDP) was applied solely with nasal continuous positive airway pressure support. In the nHF cohort (2015-2018) nCPAP was used and followed by nHF therapy to deliver CDP. Bodyweight and length at six months CA were used as a proxy for lung growth. We also assessed the impact on respiratory management and neonatal morbidity. Multivariate analysis was performed after multiple imputation, using a linear regression adjusting for confounding variables. Results: Of the 598 eligible infants, 313 infants were included in the nCPAP cohort, and 285 infants in the nHF cohort. The analyses showed no differences between the nCPAP and nHF cohort in body weight (7.29 vs 7.31 kilogram, 95%CI -0.14-0.20, p=0.71), and length (66.6 vs 66.8 centimeters (95%CI -0.30- 0.81, p=0.26) at six months CA. No differences in moderate/severe bronchopulmonary dysplasia (BPD) were reported, but nHF implementation was associated with longer CDP duration, a trend towards more days on supplemental oxygen, and shift from moderate to severe BPD. Conclusions: Implementation of nHF did not impact body growth, which is associated with lung growth, at six months CA in preterm infants born <30 weeks.

Journal Section:
Novel Insights from Clinical Practice
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution 4.0 International License .
Attribution